Collegium Pharmaceutical earnings were $43.9M for the trailing 12 months ending Mar 31, 2025, with -51.6% growth year over year. The latest COLL earnings report on Mar 31, 2025 announced Q1 2025 earnings of $2.4M, down 80.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, COLL reported annual earnings of $69.2M, with 43.7% growth.
COLL past earnings growth
How has COLL's earnings growth performed historically?
Collegium Pharmaceutical Earnings Reports & History FAQ
What were Collegium Pharmaceutical's earnings last quarter?
On COLL's earnings call on Invalid Date, Collegium Pharmaceutical (NASDAQ: COLL) reported Q1 2025 earnings per share (EPS) of $0.08, up 90.7% year over year. Total COLL earnings for the quarter were $2.42 million. In the same quarter last year, Collegium Pharmaceutical's earnings per share (EPS) was $0.86.
Is Collegium Pharmaceutical profitable or losing money?
As of the last Collegium Pharmaceutical earnings report, Collegium Pharmaceutical is currently profitable. Collegium Pharmaceutical's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $43.89 million, a 52.95% decrease year over year.
What was COLL's earnings growth in the past year?
As of Collegium Pharmaceutical's earnings date in Invalid Date, Collegium Pharmaceutical's earnings has grown -51.6% year over year. This is 78.72 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 27.12%. COLL earnings in the past year totalled $43.89 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.